Citations

Clear

4207 citation(s) found for "Chen, Yu".

The relationship between performance validity test failure, fatigue, and psychological functioning in Long COVID
Minor, Greta , Kessler, Olivia R., Fry, Laura, Huizenga, Brooke , Naini, Savana M. , Shen, Chen , Wiitala, Sophie J., Eskridge, Courtney, Holker, Erin , Logemann, Allison, Waldron, Eric J. , Whiteside, Douglas M. , Basso, Michael R. , Waldron, Eric J , Whiteside, Douglas , Johnson, Sara

Mayo Clinic

The Clinical Neuropsychologist | March 8, 2025 | Volume: 40 | Issue: 1 | Pages: 242-257

10.1080/13854046.2025.2476798 | PMID 40056074 Get It

Analysis of the BraTS 2023 Intracranial Meningioma Segmentation Challenge
LaBella, Dominic , Baid, Ujjwal , Khanna, Omaditya , McBurney-Lin, Shan , McLean, Ryan, Rashid, Arif , Altes, Talissa A. , Bhalerao, Radhika , Dhemesh, Yaseen , Hilal, Fathi , Janas, Anastasia , Kazerooni, Anahita Fathi , Kent, Collin , Leu, Kevin , Maleki, Nazanin , Pajot, Maxence , Saluja, Rachit , Wang, Chunhao , Warman, Pranav , Adewole, Maruf , Albrecht, Jake, Anwar, Syed Muhammad , Bergquist, Timothy , Chen, Sully Francis, Conte, Gian-Marco, Eddy, J. Mark , Ezhov, Ivan , Jiang, Zhifan , Johanson, Elaine, Linguraru, Marius George , Liu, Xinyang , Meier, Zeke, Shinohara, Russell Takeshi, Abayazeed, Aly, Akinola, Rachel , Bilello, Michel , Verdier, Maria Correia de, Moassefi, Mana, Pease, Matthew W., Vollmuth, Phillipp, Diffley, David, Hussain, Ali , Fehringer, Pascal, Bronstein, Yulia, Deptula, Lisa, Stein, Evan G. , Taherzadeh, Mahsa , Oliveira, Eduardo Portela de, Haughey, Aoife , Kontzialis, Marinos , Saba, Luca , Turner, Benjamin , Brüßeler, Melanie, Gkampenis, Athanasios , Weiss, David Maximilian, Mansour, Aya, Shawali, Islam H., Yordanov, Nikolay , Hourani, Roula , Moshebah, Mohammed Yahya, Abouelatta, Ahmed Magdy, Willms, Klara, Martin, Dann C., Okar, Abdullah , Kite, Dominic , Haider, Muhammad Ammar , Aristizábal, Alejandro , Karargyris, Alexandros , Kassem, Hasan , Sheller, Micah , Alonso‐Basanta, Michelle , McLean, Ryan, Nedelec, Pierre , Rashid, Arif, Tahon, Nourel Hoda , Godfrey, Devon , Floyd, Scott , Kirkpatrick, John P. , Kofler, Florian , Menze, Bjoern H. , Reitman, Zachary J. , Rudie, Jeffrey D. , Velichko, Yury , Anazodo, Udunna , Chung, Verena , Chai, Rong, Dako, Farouk , Eddy, James, Khalili, Nastaran , Iglesias, Juan Eugenio , Leemput, Koen Van , Li, Hongwei , Mahtabfar, Aria , Moawad, Ahmed W. , Mongan, John , Piraud, Marie , Shinohara, Russell Taki , Wiggins, Walter F. , Jakab, András Áron , Verdier, Maria Correia de , Crivellaro, Priscila Sacilotto , Davatzikos, Christos , Farahani, Keyvan , Freymann, John , Hess, Christopher Paul , Huang, Raymond Y. , Lohmann, Philipp , Moassefi, Mana , Sollmann, Nico , Nandolia, Khanak , Warren, Daniel I, Saba, Luca , Ansari, Shehbaz , Stein, Joel M. , Rizvi, Tanvir , D’Anna, Gennaro , Taha, Ahmed , Sharifi, Yasaman , Faghani, Shahriar , Pinho, Marco C. , Pati, Sarthak , Villanueva-Meyer, Javier E. , Rauschecker, Andreas M. , Nada, Ayman , Aboian, Mariam , Flanders, Adam E , Wiestler, Benedikt , Bakas, Spyridon , Calabrese, Evan

Mayo Clinic

Machine Learning for Biomedical Imaging | March 7, 2025 | Volume: 3 | Issue: March 2025 | Pages: 38-58

10.59275/j.melba.2025-bea1 Get It

We describe the design and results from the BraTS 2023 Intracranial Meningioma Segmentation Challenge. The BraTS Meningioma Challenge differed from prior BraTS Glioma challenges in that it focused on meningiomas, which are typically benign extra-axial tumors with diverse radiologic and anatomical presentation and a propensity for multiplicity. Nine participating teams each developed deep-learning automated segmentation models using image data from the largest multi-institutional systematically expert annotated multilabel multi-sequence meningioma MRI dataset to date, which included 1000 training set cases, 141 validation set cases, and 283 hidden test set cases. Each case included T2, FLAIR, T1, and T1Gd brain MRI sequences with associated tumor compartment labels delineating enhancing tumor, non-enhancing tumor, and surrounding non-enhancing FLAIR hyperintensity. Participant automated segmentation models were evaluated and ranked based on a scoring system evaluating lesion-wise metrics including dice similarity coefficient (DSC) and 95% Hausdorff Distance. The top ranked team had a lesion-wise median dice similarity coefficient (DSC) of 0.976, 0.976, and 0.964 for enhancing tumor, tumor core, and whole tumor, respectively and a corresponding average DSC of 0.899, 0.904, and 0.871, respectively. These results serve as state-of-the-art benchmarks for future pre-operative meningioma automated segmentation algorithms. Additionally, we found that 1286 of 1424 cases (90.3%) had at least 1 compartment voxel abutting the edge of the skull-stripped image edge, which requires further investigation into optimal pre-processing face anonymization steps.
Macrophage peroxisomes guide alveolar regeneration and limit SARS-CoV-2 tissue sequelae
Wei, Xiaoqin , Qian, Wei , Narasimhan, Harish , Chan, T. K., Liu, Xue , Arish, Mohd , Young, Scott , Li, Chaofan , Cheon, In Su , Yu, Qing , Santos, Gislane de Almeida , Yeatts, Eric V., Spear, Olivia J., Yi, Mou, Hahn, Young S. , Kaplan, Mark H. , Sperling, Anne I. , Shim, Yun M. , Vassallo, Robert , Chen, Peter , Roden, Anja C. , Que, Jianwen , Chan, Ting , Young, Samuel , de Almeida Santos, Gislane , Zhao, Xiao-Yu , Yeatts, Eric V , Parimon, Tanyalak , Fang, Yinshan , Hahn, Young S , Bullock, Timothy N J , Somerville, Lindsay A , Kaplan, Mark H , Sperling, Anne I , Shim, Yun Michael , Vassallo, Robert , Chen, Peter , Ewald, Sarah E , Roden, Anja C , Que, Jianwen , Jiang, Dianhua , Sun, Jie , Li, Chaofan , Yi, Megan, Somerville, Lindsay , Sun, Jie

Mayo Clinic

Science | March 6, 2025 | Volume: 387 | Issue: 6738 | Pages: No page available

10.1126/science.adq2509 | PMID 40048515 Get It

Peroxisomes are vital but often overlooked metabolic organelles. We found that excessive interferon signaling remodeled macrophage peroxisomes. This loss of peroxisomes impaired inflammation resolution and lung repair during severe respiratory viral infections. Peroxisomes were found to modulate lipid metabolism and mitochondrial health in a macrophage type-specific manner and enhanced alveolar macrophage-mediated tissue repair and alveolar regeneration after viral infection. Peroxisomes also prevented excessive macrophage inflammasome activation and IL-1β release, limiting accumulation of KRT8 high dysplastic epithelial progenitors following viral injury. Pharmacologically enhancing peroxisome biogenesis mitigated both acute symptoms and post-acute sequelae of COVID-19 (PASC) in animal models. Thus, macrophage peroxisome dysfunction contributes to chronic lung pathology and fibrosis after severe acute respiratory syndrome coronavirus 2 infection.
Low-Dose Valacyclovir in Herpes Zoster Ophthalmicus
Cohen, Elisabeth J. , Liu, Mengling , Baratz, Keith H. , Mian, Shahzad I., Choulakian, Mazen Y., Warner, David B., Lu, Ying , Twi-Yeboah, Alberta , Kim, Jiyu , Lopez-Jimenez, Carlos, Laury, Sarah, Jeng, Bennie H., Weissbart, Sarah B. , Abazari, Azin, Chou, Timothy , Chang, Eileen , Amescua, Guillermo , Koo, Ellen, Galor, Anat , Berestka, John S., Nanji, Afshan, Stutzman, Richard D., Clements, John, Davies, Emma , Saeed, Hajirah N. , Ciralsky, Jessica, Fernández, A. Gómez-Bastero , Sippel, Kimberly C. , Perez-Quinones, Victor L, Daluvoy, Melissa B. , Liu, Katy C., Ewald, M., Groos, Erich B, Chang, Bernard, Shivitz, Ira A., Hill, Jordan , Fowler, Priscilla G., Read, Russell W. , Geggel, Harry S. , Rony, Sayegh, Rapuano, Christopher J. , Meghpara, Beeran, Holland, Gary N. , Irvine, John, Aldave, Anthony J. , Edmund, Tsui, Chen, Judy , Honig, Marc A, Snyder, Lee A, Lubniewski, Anthony J., Katz, Douglas, Capoor, Seema, Gonzales, John, Keenan, Jeremy, Morkin, Melina I., Kenyon, Kenneth R., Lee, William B., Christenbury, Joseph, LaMattina, Kara C. , Negahban, Kambiz, Rao, Ronihi, Ament, Christine S, Lopatynsky, Marta O., Barbato, John D, Sarkar, Jayati S, Macsai, Marian S., Herz, Joshua B, Al-Mohtaseb, Zaina , Matoba, Alice Y., Cooney, Theresa, Sugar, Alan , Shtein, Roni M., Nehls, Sarah, Warner, Evan J. , Nettune, Greg, Bowman, Brad, Gelender, Henry, Alexander, Jamie K. , McCall, Tyrone, Zaffos, Joshua, Beebe, Walter E., Potts, Luke B. , Lustbader, Jay M., Oboh-Weilke, Aruoriwo, Hammersmith, K.M., Orlin, Stephen E., Nagra, Parveen K., Sulewski, Michael E., Bunya, Vatinee Y. , Shafer, Brian M. , Viriya, Elizabeth T., Qureshi, Anam, Lazzaro, Douglas R., Palazzolo, Laura , Goyal, Himani , Schrack, Katie E, Raber, Irving M. , Ayres, Brandon D. , Finklea, Brenton, Reeves, Sherman W., Awad, Omar E, Hardten, David R., Reilly, Charles, Flynn, William J., Rashid, Edward D, Wen, Angie E, Harris, David J. , Shaik, Neha, Seedor, John A., Rosenfeld, Steven I., Winnick, Marc , Amir, Ahmad Fitri , Sherman, Mark D., Chaon, Benjamin, Soukiasian, Sarkis H., Rao, Naveen K. , Steiner, Anne, Winokur, Jules , Udell, Ira J., Shih, Carolyn, Gorski, Matthew , Schrier, Amilia, Lobo-Chan, Ann-Marie , Sugar, Joel, Munir, Wuqaas W, Sunshine, Sarah B. , Miller, Donald M. , Gensheimer, William G. , Zegans, Michael E. , Weiss, Jayne S. , Bernal, María José , Barron, Bruce J., Hindman, Holly B. , Wise, R., Gelston, Christopher D. , Taravella, Michael J. , Davidson, Richard S. , Tran, Uyen, Bartley, Jeremy, McCulley, James P., Verity, Steven M., Bowman, Wayne, Blomquist, Preston H. , Mootha, V. Vinod , Thorne, George, Renucci, Ann M, Verdier, David D. , Sivaraman, K. R., Nordlund, Michael L., Hwang, Frank S. , Affeldt, John E., Ingraham, Herbert J., Guibord, Nathalie M., Dobbins, Kendall, Thareja, Tarika , Zaugg, Brian , Mifflin, Mark D., FORSTOT, S. LANCE, Fish, Robert A, Repine, Karen, Wildes, Michael, Estopinal, Christopher B., Brown, Donna, Koreishi, Aaleya, Ple-plakon, Patricia, Clemons, Carol S., Ashe, S, Bonaffini, Sarah G. , Houser, Kourtney, Wallace, M. Christopher , Wesberry, Jesse M, Yeung, Sonia N. , Noordeh, Nima, Faucher, Anne, Robert, Marie‐Claude , Rullo, Jacob, Johnson, Davin , Mah, Dean, Chew, Hall F., Hassonlou, Mojgan, Liu, Shaohui , Eikenberry, Jennifer , Yung, Chi-Wah, Shen, Joanne F , Yu, Charles, Ta, Christopher N. , Goins, Kenneth M., Sutphin, John E., Svanda, Kerri, Keppol, Stacy, Rostov, Audrey Talley, Vyas, Neil , Hsu, Kimberly , Goodman, Gerri, McHam, Lisa, Oates, Dale, Rizkalla, Ramy, Shukla, Anita N. , Veena, Mathew , See, Craig W. , Feder, Robert S., Baqai, Jeanine, Basti, Surendra, Haddadin, Ramez I., You, Jae Young , Dixit, Lena, Patel, Ravi H, Golde, Kimberly T, Zaidman, Gerald W., Mahesh, Sankara, Wesolosky, Jason D., Jeffrey, Helen, Mannis, Mark J., Meyer, Jay J. , Niederer, Rachael L. , Colby, Kathryn , McLeod, Stephen D. , Melia, Michele , Sugar, Elizabeth A. , Taylor, Carol R., Nagel, Maria A. , Lass, Jonathan H. , Lu, Ying , Jeng, Bennie H. , Troxel, Andrea B. , Hochman, Judith S. , Mian, Shahzad I. , Warner, David B., Lu, Ying, Lee, Ting‐Fang , Tonk, Rahul Singh , Martinez, Jaime D. , Patel, Sanjay V. , Chamberlain, Winston , Chodosh, James , Fernandez, Ana G Alzaga, Hill, Jordan, Omar, Ahmed F. , Syed, Zeba A. , Lee, Olivia, Irvine, John, Deng, Sophie X. , Huang, Andrew , Margolis, Todd P. , Seitzman, Gerami D. , Hamrah, Pedram , Lee, Hyunjoo, Weikert, Mitchell P. , Hood, Christopher T. , Woodward, Maria A. , Shtein, Roni Mintz , Zaffos, Joshua, Prescott, Christina R. , Haberman, Ilyse D. , Ritterband, David C. , Harris, David J, Ahmad, Sumayya , Amir, Ahmad, Srikumaran, Divya S. , Akpek, Esen K. , Tu, Elmer Yuchen , Miller, Donald M, Bernal, Maria, Barron, Bruce, Wise, Ronald, Shieh, Christine , Thorne, George, Renucci, A., Sivaraman, Kavitha, Affeldt, John, Guibord, Nathalie M, Lin, Amy , Patel, Ravi, Asbell, Penny A. , Wallace, Michael, Iovieno, Alfonso , Teichman, Joshua C. , Robert, Marie-Claude , Harissi‐Dagher, Mona , Baxter, Stephanie A. , Benson, Matthew, Tone, Stephan Ong , Yung, C.–W., Lin, Charles C. , Vyas, Neil M, Oates, Dale, Veena, Mathew, Goshe, Jeffrey M. , Sharma, Vikas , Miller, Darby D. , Ma, Jeffrey H, Dupps, William Joseph

Mayo Clinic

JAMA Ophthalmology | March 6, 2025 | Volume: 143 | Issue: 4 | Pages: 269

10.1001/jamaophthalmol.2024.6114 | PMID 40048183 Get It

Importance High-quality evidence regarding suppressive valacyclovir treatment in herpes zoster ophthalmicus (HZO) is necessary to guide care. Objective To determine whether suppressive valacyclovir compared with placebo delays the occurrence of new or worsening stromal keratitis (SK), endothelial keratitis (EK), iritis, or dendriform epithelial keratitis (DEK) during 12 months of treatment and if treatment benefit persisted at 18 months (secondary end point). Design, Setting, and Participants The Zoster Eye Disease Study (ZEDS) was a randomized clinical trial conducted in 95 sites from November 2017 to June 2024. Immunocompetent, nonpregnant adults with a history of an HZO rash, documented active keratitis or iritis within 1 year, and an estimated glomerular filtration rate of 45 mL/min/1.73 m 2 or greater were eligible. After determined to be eligible, participants were randomized in 4 strata: age at onset (<60 years vs ≥60 years) and disease duration (<6 months vs ≥6 months). Interventions A total of 12 months of double-masked daily valacyclovir, 1000 mg, or placebo. Main Outcomes and Measures The primary outcome was time to first occurrence within 12 months of new or worsening SK, EK, iritis, or DEK. Results A total of 527 participants (median [IQR] age, 60 [50-68] years; 266 female [50.5%]; 266 in the valacyclovir group; 261 in the placebo group) were randomized in 4 strata; 481 completed 12 months, and 460 completed 18 months. Data were analyzed by intention to treat. At 12 months, primary end points occurred in 86 participants (33%) assigned to placebo and 74 (28%) assigned to valacyclovir, and at 18 months in 104 participants (40%) assigned to placebo and 86 (32%) assigned to valacyclovir. The hazard ratio (HR) of the primary end point at 12 months was 0.77 for participants taking valacyclovir vs placebo (HR, 0.77; adjusted 95% CI, 0.56-1.05; P = .09) and 0.73 at the secondary end point at 18 months (HR, 0.73; adjusted 95% CI, 0.55-0.97; P = .03). There was a reduction of multiple other secondary end points at 12 months (HR, 0.70; 95% CI, 0.52-0.95; P = .02) and 18 months (HR, 0.72; 95% CI, 0.55-0.95; P = .02). Conclusions and Relevance Although the primary outcome did not show a benefit of suppressive valacyclovir treatment, secondary study outcomes showed treatment superiority at the 18-month end point and reduced number of multiple episodes of keratitis or iritis at both 12 and 18 months. These results support consideration of 1 year of suppressive valacyclovir treatment for HZO. Trial Registration ClinicalTrials.gov Identifier: NCT03134196
Low-Dose Valacyclovir for Postherpetic Neuralgia in the Zoster Eye Disease Study
Warner, David, Jeng, Bennie H., Kim, Jiyu , Liu, Mengling , Baratz, Keith H. , Mian, Shahzad I., Choulakian, Mazen Y., Meyer, Jay J. , Lu, Ying , Twi-Yeboah, Alberta , Lopez-Jimenez, Carlos, Laury, Sarah, Cohen, Elisabeth J. , Weissbart, Sarah B. , Abazari, Azin, Chou, Timothy , Chang, Eileen , Amescua, Guillermo , Koo, Ellen, Galor, Anat , Berestka, John S., Nanji, Afshan, Stutzman, Richard D., Clements, John, Davies, Emma , Saeed, Hajirah N. , Ciralsky, Jessica, Fernández, A. Gómez-Bastero , Sippel, Kimberly C. , Perez-Quinones, Victor L, Daluvoy, Melissa B. , Liu, Katy C., Ewald, M., Groos, Erich B, Chang, Bernard, Shivitz, Ira A., Hill, Jordan , Fowler, Priscilla G., Read, Russell W. , Geggel, Harry S. , Rony, Sayegh, Rapuano, Christopher J. , Meghpara, Beeran, Holland, Gary N. , Irvine, John, Aldave, Anthony J. , Edmund, Tsui, Chen, Judy , Honig, Marc A, Snyder, Lee A, Lubniewski, Anthony J., Katz, Douglas, Capoor, Seema, Gonzales, John, Morkin, Melina I., Kenyon, Kenneth R., Lee, William B., Christenbury, Joseph, LaMattina, Kara C. , Negahban, Kambiz, Rao, Ronihi, Ament, Christine S, Lopatynsky, Marta O., Barbato, John D, Sarkar, Jayati S, Macsai, Marian S., Herz, Joshua B, Al-Mohtaseb, Zaina , Matoba, Alice Y., Cooney, Theresa, Hood, Christopher , Sugar, Alan M., Shtein, Roni M., Nehls, Sarah, Warner, Evan J. , Nettune, Greg, Bowman, Brad, Gelender, Henry, Alexander, Jamie K. , McCall, Tyrone, Zaffos, Joshua, Beebe, Walter E., Potts, Luke B. , Lustbader, Jay M., Oboh-Weilke, Aruoriwo, Hammersmith, K.M., Orlin, Stephen E., Nagra, Parveen K., Sulewski, Michael E., Bunya, Vatinee Y. , Shafer, Brian M. , Viriya, Elizabeth T., Qureshi, Anam, Lazzaro, Douglas R., Palazzolo, Laura , Goyal, Himani , Schrack, Katie E, Raber, Irving M. , Ayres, Brandon D. , Finklea, Brenton, Reeves, Sherman W., Awad, Omar E, Hardten, David R., Reilly, Charles, Flynn, William J., Rashid, Edward D, Wen, Angie E, Shaik, Neha, Seedor, John A., Rosenfeld, Steven I., Winnick, Marc , Amir, Ahmad, Sherman, Mark D., Chaon, Benjamin, Soukiasian, Sarkis H., Rao, Naveen K. , Steiner, Anne, Winokur, Jules , Udell, Ira J., Shih, Carolyn, Gorski, Matthew , Schrier, Amilia, Lobo-Chan, Ann-Marie , Sugar, Joel, Munir, Wuqaas W, Sunshine, Sarah B. , Miller, Donald M. , Gensheimer, William G. , Zegans, Michael E. , Weiss, Jayne S. , Bernal, M.L. , Barron, Bruce, Hindman, Holly B. , Wise, Ronald E. , Gelston, Christopher D. , Taravella, Michael J. , Davidson, Richard S. , Tran, Uyen, Bartley, Jeremy, McCulley, James P., Verity, Steven M., Bowman, Wayne, Blomquist, Preston H. , Mootha, V. Vinod , Thorne, George, Renucci, A., Verdier, David D. , Sivaraman, K. R., Nordlund, Michael L., Hwang, Frank S. , Affeldt, John, Ingraham, Herbert J., Guibord, Nathalie M, Dobbins, Kendall, Thareja, Tarika , Zaugg, Brian , Mifflin, Mark D., Forstot, S. Lance, Fish, Robert A, Repine, Karen, Wildes, Michael, Estopinal, Christopher B., Brown, Donna, Koreishi, Aaleya, Ple-plakon, Patricia, Clemons, Carol S., Patel, Ravi , Ashe, Sanda, Bonaffini, Sarah G. , Houser, Kourtney, Wallace, Michael A., Wesberry, Jesse M, Yeung, Sonia N. , Noordeh, Nima, Faucher, Anne, Rullo, Jacob, Johnson, Davin , Mah, Dean, Benson, Matthew , Chew, Hall F., Hassonlou, Mojgan, Liu, Shaohui , Eikenberry, Jennifer , Yung, Chi-Wah, Shen, Joanne F , Lin, Charles C. , Yu, Charles, Ta, Christopher N. , Goins, Kenneth M., Sutphin, John E., Svanda, Kerri, Keppol, Stacy, Rostov, Audrey Talley, Vyas, Neil , Hsu, Kimberly, Goodman, Gerri, McHam, Lisa, Oates, Dale, Rizkalla, Ramy, Shukla, Anita N. , Veena, Mathew , See, Craig W. , Feder, Robert S., Baqai, Jeanine, Basti, Surendra, Haddadin, Ramez I., You, Jae Young , Dixit, Lena, Patel, Ravi H, Golde, Kimberly T, Zaidman, Gerald W., Mahesh, Sankara, Sharma, Vikas, Wesolosky, Jason D., Jeffrey, Helen, Mannis, Mark J., Niederer, Rachael L. , Lu, Ying , Jeng, Bennie H. , Troxel, Andrea B. , Hochman, Judith S. , Mian, Shahzad I. , Lee, Ting‐Fang , Tonk, Rahul Singh , Martinez, Jaime D. , Patel, Sanjay V. , Chamberlain, Winston , Chodosh, James , Fernandez, Ana G Alzaga, Perez-Quinones, Victor L, Hill, Jordan, Omar, Ahmed F. , Syed, Zeba A. , Lee, Olivia, Irvine, John, Deng, Sophie X. , Edmund, Tsui, Huang, Andrew , Margolis, Todd P. , Seitzman, Gerami D. , Keenan, Jeremy David , Hamrah, Pedram , Lee, Hyunjoo, Barbato, John D, Weikert, Mitchell P. , Hood, Christopher, Woodward, Maria A. , Sugar, Alan, Shtein, Roni Mintz , Prescott, Christina R. , Haberman, Ilyse D. , Schrack, Katie E, Ritterband, David C. , Harris, David J, Ahmad, Sumayya , Srikumaran, Divya S. , Akpek, Esen K. , Tu, Elmer Yuchen , Miller, Donald M, Bernal, Maria, Shieh, Christine , Thorne, George, Sivaraman, Kavitha, Lin, Amy , Repine, Karen, Asbell, Penny A. , Ashe, S, Wallace, Michael, Iovieno, Alfonso , Teichman, Joshua C. , Robert, Marie-Claude , Harissi‐Dagher, Mona , Baxter, Stephanie A. , Benson, Matthew, Tone, Stephan Ong , Hassonlou, Mojgan, Yung, C.–W., Svanda, Kerri, Keppol, Stacy, Vyas, Neil M, McHam, Lisa, Veena, Mathew, Goshe, Jeffrey M. , Miller, Darby D. , Ma, Jeffrey H

Mayo Clinic

JAMA Ophthalmology | March 6, 2025 | Volume: 143 | Issue: 4 | Pages: 277

10.1001/jamaophthalmol.2024.6113 | PMID 40048191 Get It

Importance Evidence regarding suppressive valacyclovir treatment on postherpetic neuralgia is necessary to guide care. Objective To test the hypothesis that suppressive treatment with 1000 mg/d of oral valacyclovir for 12 months reduces the prevalence, severity, and duration of postherpetic neuralgia compared with placebo at 12 and 18 months in participants with herpes zoster ophthalmicus (HZO). Design, Setting, and Participants Multicenter, placebo-controlled randomized clinical trial including 527 immunocompetent, nonpregnant adults with history of HZO rash, documented keratitis, or iritis within 1 year and an estimated glomerular filtration rate of 45 mL/min/1.73 m 2 or greater. The study was conducted at 95 participating sites (in Canada, New Zealand, and the US) from November 2017 to June 2024 and participant visits occurred every 3 months. Intervention Treatment with 1000 mg/d of valacyclovir or placebo for 12 months. Main Outcomes and Measures Prevalence of postherpetic neuralgia, severity as determined by pain score (a score of ≥3 on a scale of 1-10), pain duration (≥3 months after HZO onset), and total daily dose of pain medication. Results Of the 527 participants (490 completed 12 months of treatment and 460 completed 18 months), 73 (14%) had postherpetic neuralgia and were analyzed by age at HZO onset (<60 years or ≥60 years) and disease duration (recent [<6 months] or chronic [≥6 months]). Of the 73 participants with postherpetic neuralgia (34 in the valacyclovir group and 39 in the placebo group), the mean age was 62.4 years (SD, 13.6 years), 59% were female, 5% were Black or African American, and 10% were Hispanic. The prevalence of postherpetic neuralgia at 12 months was not reduced by valacyclovir (12/32 [38%]) compared with placebo (14/35 [40%]) (between-group difference, 2.5% [95% CI, −20.8% to 25.8%]; P >.99). The participants who were younger than 60 years at HZO onset and had a chronic disease duration had lower pain scores in the valacyclovir group (mean score, 0.3 [SD, 0.9]) vs the placebo group (mean score, 0.8 [SD, 1.9]) at 12 months ( P = .045) and at 18 months (mean score, 0.2 [SD, 0.9] vs 1.0 [SD, 2.3], respectively; P = .02). There was a decrease in pain duration in the valacyclovir group at 18 months (mean, 13.6 [SD, 11.4] months) vs the placebo group (mean, 18.7 [SD, 29.5] months) (linear mixed-effects model between-group difference, −3.39 months [95% CI, −6.73 to −0.04 months]; P = .046). The total daily dose of neuropathic pain medication was lower in the valacyclovir group (mean, 271.4 [SD, 593.8] mg/d) vs the placebo group (mean, 363.4 [SD, 592.2] mg/d) at 12 months (linear mixed-effects model P = .006) and at 18 months (mean, 209.0 [SD, 412.8] mg/d vs 286.2 [SD, 577.9] mg/d, respectively; linear mixed-effects model P = .01). Conclusions and Relevance One year of suppressive treatment with valacyclovir was associated with a lower dosage of neuropathic pain medication. Participants in the valacyclovir group, who were younger at HZO onset and had a chronic disease duration, had lower pain scores. These secondary outcomes support consideration of 1 year of suppressive treatment with valacyclovir to reduce dosage of pain medications and pain due to HZO. Trial Registration ClinicalTrials.gov Identifier: NCT03134196
Intensity-Based Assessment of Hippocampal Segmentation Algorithms Using Paired Precontrast and Postcontrast MRI
Cramer, Justin , Baxter, Leslie C. , Lang, Harrison, Parker, Jonathon J. , Matthees, Nicholas , Ikuta, Ichiro , Wang, Yalin , Parker, Jonathon, Chen, Alicia , Matthees, Nicholas , Ikuta, Ichiro , Wang, Yalin , Baxter, Leslie C. , Lang, Harrison, Chen, Alicia M. , Zhou, Yuxiang

Mayo Clinic

Bioengineering | March 4, 2025 | Volume: 12 | Issue: 3 | Pages: 258

10.3390/bioengineering12030258 | PMID 40150721 Get It

Hippocampal segmentation is essential in neuroimaging for evaluating conditions like Alzheimer’s dementia and mesial temporal sclerosis, where small volume changes can significantly impact normative percentiles. However, inaccurate segmentation is common due to the inclusion of non-hippocampal structures such as choroid plexus and cerebrospinal fluid (CSF), leading to volumetric overestimation and confounding of functional analyses. Current methods of assessment largely rely on virtual or manual ground truth labels, which can fail to capture these inaccuracies. To address this shortcoming, this study introduces a more direct voxel intensity-based method of segmentation assessment. Using paired precontrast and postcontrast T1-weighted MRIs, hippocampal segmentations were refined by adding marginal gray matter and removing marginal CSF and enhancement to determine a total required correction volume. Six segmentation algorithms—e2dhipseg, HippMapp3r, hippodeep, AssemblyNet, FastSurfer, and QuickNat—were implemented and compared. HippMapp3r and e2dhipseg, followed closely by hippodeep, exhibited the least total correction volumes, indicating superior accuracy. Dedicated hippocampal segmentation algorithms outperformed whole-brain methods.
Engineering Extracellular Vesicles Secreted by Human Brain Organoids with Different Regional Identity
Ene, Justice , Esmonde, Colin , Kanekiyo, Takahisa , Sun, Li , Li, Yan , Sun, Li , Li, Yan , Liu, Chang , Chen, Xingchi , Zeng, Changchun

Mayo Clinic

ACS Applied Materials & Interfaces | March 3, 2025 | Volume: 17 | Issue: 10 | Pages: 15145-15162

10.1021/acsami.4c22692 | PMID 40030083 Get It

Bacteriophage therapy for multidrug-resistant infections: current technologies and therapeutic approaches
Pérez-Rodríguez, Saumel , Dharmaraj, Tejas , Chang, Tony H. , Green, Sabrina I. , Sacher, Jessica , Kim, Minyoung Kevin , Suh, Gina A. , Cullen, Grace , Li, Zhiwei , Chen, Qingquan , Lavigne, Rob , Pirnay, Jean‐Paul , Bollyky, Paul L.

Mayo Clinic

Journal of Clinical Investigation | March 2, 2025 | Volume: 135 | Issue: 5 | Pages: No page available

10.1172/jci187996 | PMID 40026251 Get It

Bacteriophage (phage) therapy has emerged as a promising solution to combat the growing crisis of multidrug-resistant (MDR) infections. There are several international centers actively engaged in implementation of phage therapy, and recent case series have reported encouraging success rates in patients receiving personalized, compassionate phage therapy for difficult-to-treat infections. Nonetheless, substantial hurdles remain in the way of more widespread adoption and more consistent success. This Review offers a comprehensive overview of current phage therapy technologies and therapeutic approaches. We first delineate the common steps in phage therapy development, from phage bank establishment to clinical administration, and examine the spectrum of therapeutic approaches, from personalized to fixed phage cocktails. Using the framework of a conventional drug development pipeline, we then identify critical knowledge gaps in areas such as cocktail design, formulation, pharmacology, and clinical trial design. We conclude that, while phage therapy holds promise, a structured drug development pipeline and sustained government support are crucial for widespread adoption of phage therapy for MDR infections.
Immediate Reduction in Left Ventricular Contractility After Mitral Transcatheter Edge‐to‐Edge Repair Is Associated With Lower Rates of Heart Failure Hospitalizations
Chen, Ke‐Wei , Chang, Jeng-Sheng , Sularz, Agata , Russo, Gerardo Lo , Chang, Shih‐Sheng , Liu, C H, Alkhouli, Mohamad , Chang, Ju-Hsin , Lo Russo, Gerardo , Saleh, Ghasaq, Chang, Shih-Sheng , Liu, Chia-Hao , Alkhouli, Mohamad , Sularz, Agata , Saleh, Ghasaq

Mayo Clinic

Journal of the American Heart Association | February 26, 2025 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/jaha.124.037545 | PMID 40008509 Get It

Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition
Fiorica, Peter N. , Golmard, Lisa , Kim, Jung , Bao, Riyue , Lin, Frank Y. , Roy, Angshumoy , Pribnow, Allison , Perrino, Melissa R. , Masliah‐Planchon, Julien , Michalak-Provost, Sophie , Wong, Jennifer , Filser, Mathilde , Bourdeaut, Franck , Brahimi, Afane, Ingster, Olivier, Jackson, Sarah A. , Sasaki, Mark M. , Fowler, Trent, Ng, Anita , Corbett, Ryan J. , Kaufman, Rebecca , Haley, Jeremy S. , Carey, David J. , Huang, Kuan‐lin , Diskin, Sharon J. , Al‐Kateb, Hussam , Schultz, Kris Ann P. , Onel, Kenan , Stoppa-Lyonnet, Dominique , Bourdeaut, Franck , Brahimi, Afane , Ingster, Olivier , Saulnier Sholler, Giselle , Jackson, Sarah A , Sasaki, Mark M , Fowler, Trent , Ng, Anita , Corbett, Ryan J , Kaufman, Rebecca S , Haley, Jeremy S , Carey, David J , Huang, Kuan-Lin , Diskin, Sharon J , Rokita, Jo Lynne , Al-Kateb, Hussam , McGee, Rose B , Schiffman, Joshua D , Chen, Kenneth S , Stewart, Douglas R , Parsons, D Williams , Plon, Sharon E. , Schultz, Kris Ann P , Onel, Kenan , Perrino, Melissa R , Lin, Frank Y , Stoppa‐Lyonnet, Dominique , Rokita, Jo Lynne , Chen, Kenneth , Parsons, D. Williams

Mayo Clinic

Clinical Cancer Research | February 24, 2025 | Volume: 31 | Issue: 8 | Pages: 1491-1503

10.1158/1078-0432.ccr-24-2785 | PMID 39992227 Get It

Abstract Purpose: DROSHA, DGCR8, and DICER1 regulate miRNA biogenesis and are commonly mutated in cancer. Although DGCR8 and DICER1 germline pathogenic variants (GPV) cause autosomal dominant tumor predisposition, no association between DROSHA GPVs and clinical phenotypes has been reported. Experimental Design: After obtaining informed consent, sequencing was performed on germline and tumor samples from all patients. The occurrence of germline DROSHA GPVs was investigated in large pediatric and adult cancer datasets. The population prevalence of DROSHA GPVs was investigated in the UK Biobank and Geisinger DiscovEHR cohorts. Results: We describe nine children from eight families with heterozygous DROSHA GPVs and a diagnosis of pineoblastoma (n = 8) or Wilms tumor (n = 1). A somatic second hit in DROSHA was detected in all eight tumors analyzed. All pineoblastoma tumors analyzed were classified as miRNA processing–altered 1 subtype. We estimate the population prevalence of germline DROSHA loss-of-function variants to be 1:3,875 to 1:4,843 but find no evidence for increased adult cancer risk. Conclusions: This is the first report of DROSHA-related tumor predisposition. As pineoblastoma and Wilms tumor are also associated with DICER1 GPVs, our results suggest that the tissues of origin for these tumors are uniquely tolerant of general miRNA loss. The miRNA processing–altered 1 pineoblastoma subtype is associated with older age of diagnosis and better outcomes than other subtypes, suggesting DROSHA GPV status may have important clinical and prognostic significance. We suggest that genetic testing for DROSHA GPVs be considered for patients with pineoblastoma, Wilms tumor, or other DICER1-/DGCR8-related conditions and propose surveillance recommendations through research studies for individuals with DROSHA GPVs.